Monoclonal antibodies for prophylaxis and therapy of infectious diseases

• TALBOT GH, BRADLEY J, EDWARDS JE Jr et al.: Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin. Infect. Dis. (2006) 42(5):657-668.
   PubMed Web of Science ®Google Scholar
• Bad bugs, no drugs: As antibiotic R&D stagnates, a public health crisis brews. Alexandria VA: infectious disease society of America (2004).
   Google Scholar
• PROJAN S: Why is big pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. (2003) 6:427-430.
   PubMed Web of Science ®Google Scholar
• CASADEVALL A, DADACHOVA E, PIROFSKI L-A: Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. (2004) 2(9):695-703.
   PubMed Web of Science ®Google Scholar
• KELLER MA, STIEHM RE: Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. (2000) 13(4):602-614.
   PubMed Web of Science ®Google Scholar
• BAKER M: Upping the ante on antibodies. Nat. Biotech. (2005) 23(9):1065-1072.
   PubMed Web of Science ®Google Scholar
• CURNS AT, HOLMAN RC, SEJVAR JJ et al.: Infectious disease hospitalizations among older adults in the United States from 1990 through 2002. Arch. Intern. Med. (2005) 165(21):2514-2520.
   PubMed Web of Science ®Google Scholar
• WENZEL RP, EDMOND MB: The impact of hospital-acquired bloodstream infections. Emerg. Infect. Dis. (2001) 7(2):174-177.
   PubMed Web of Science ®Google Scholar
• WISPLINGHOFF H, BISCHOFF T, TALLENT SM: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. (2004) 39(3):309-317.
   PubMed Web of Science ®Google Scholar
• COSGROVE SE, QI Y, KAYE KS et al.: The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. (2005) 26(2):166-174.
   PubMed Web of Science ®Google Scholar
• APPELBAUM PC: The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. (2006) 12(Suppl. 1):16-23.
   PubMed Web of Science ®Google Scholar
• GIAMARELLOU H: Treatment options for multidrug-resistant bacteria. Expert Rev. Antiinfect Ther. (2006) 4(4):601-618.
   PubMedGoogle Scholar
• ALANIS AJ: Resistance to antibiotics: are we in the post-antibiotic era? Arch. Med. Res. (2005) 36(6):697-705.
   PubMed Web of Science ®Google Scholar
• MWINTSHI K, BRENNAN DC: Prevention and management of cytomegalovirus infection in solid-organ transplantation. Expert Rev. Antiinfect Ther. (2007) 5(2):295-304.
   PubMed Web of Science ®Google Scholar
• HODSON EM, JONES CA, STRIPPOLI GF et al.: Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev. (2007) (2):CD005129.
   PubMedGoogle Scholar
• BIGGINS SW, TERRAULT NA: Management of recurrent hepatitis C in liver transplant recipients. Infect. Dis. Clin. North Am. (2006) 20(1):155-174.
   PubMed Web of Science ®Google Scholar
• SAMUEL D, MULLER R, ALEXANDER G et al.: Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. (1993) 329(25):1842-1847.
   PubMed Web of Science ®Google Scholar
• HAN SH, OFMAN J, HOLT C et al.: An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transplant. (2000) 6(6):741-748.
   PubMed Web of Science ®Google Scholar
• TEMESGEN Z, WARNKE D, KASTEN MJ: Current status of antiretroviral therapy. Expert Opin. Pharmacother. (2006) 7(12):1541-1554.
   PubMed Web of Science ®Google Scholar
• FALSEY AR, HENNESSEY PA, FORMICA MA et al.: Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. (2005) 352(17):1749-1759.
   PubMed Web of Science ®Google Scholar
• RUPPRECHT CE, WILLOUGHBY R, SLATE D: Current and future trends in the prevention, treatment and control of rabies. Expert Rev. Antiinfect Ther. (2006) 4(6):1021-1038.
   PubMedGoogle Scholar
• FRIDKIN SK: The changing face of fungal infections in health care settings. Clin. Infect. Dis. (2005) 41(10):1455-1460.
   PubMed Web of Science ®Google Scholar
• CASADEVALL A, PIROFSKI L: Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans. Curr. Mol. Med. (2005) 5(4):421-433.
   PubMed Web of Science ®Google Scholar
• ORANGE JS, HOSSNY EM, WEILER CR et al.: Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American academy of allergy, asthma and immunology. J. Allergy Clin. Immunol. (2006) 117(4 Suppl.):S525-S553.
   PubMed Web of Science ®Google Scholar
• BOES M: Role of natural and immune IgM antibodies in immune responses. Mol. Immunol. (2000) 37(18):1141-1149.
   PubMed Web of Science ®Google Scholar
• CASADEVALL A, PIROFSKI LA: A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv. Immunol. (2006) 91:1-44.
   PubMed Web of Science ®Google Scholar
• GETAHUN A, HEYMAN B: How antibodies act as natural adjuvants. Immunol. Lett. (2006) 104(1-2):38-45.
   PubMed Web of Science ®Google Scholar
• ROMANI L: Immunity to fungal infections. Nat. Rev. Immunol. (2004) 4(1):1-23.
   PubMed Web of Science ®Google Scholar
• READING SA, DIMMOCK NJ: Neutralization of animal virus infectivity by antibody. Arch. Virol. (2007) 152(6):1047-1059.
   PubMed Web of Science ®Google Scholar
• SATOH M, IIDA S, SHITARA K: Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin. Biol. Ther. (2006) 6(11):1161-1173.
   PubMed Web of Science ®Google Scholar
• CASADEVALL A, GOLDSTEIN H, DADACHOVA E: Targeting host cells harbouring viruses with radiolabeled antibodies. Expert Opin. Biol. Ther. (2007) 7(5):595-597.
   PubMed Web of Science ®Google Scholar
• MOHAMED N, JONES SM, CASEY LS et al.: Heteropolymers: a novel technology against blood-borne infections. Curr. Opin. Mol. Ther. (2005b) 7(2):144-150.
   PubMed Web of Science ®Google Scholar
• TER MEULEN J, VAN DEN BRINK EN, POON LL et al.: Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. (2006) 3(7):E237.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN SK, RASMUSSEN LK, WEILGUNY D et al.: Manufacture of recombinant polyclonal antibodies. Biotechnol. Lett. (2007) 29(6):845-852.
   PubMed Web of Science ®Google Scholar
• VAN NUNEN AB, BAUMANN M, MANNS MP et al.: Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients. Liver (2001) 21(3):207-212.
   PubMedGoogle Scholar
• MUZZI A, MASIGNANI V, RAPPUOLI R: The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. Drug Discov. Today (2007) 12(11-12):429-439.
   PubMed Web of Science ®Google Scholar
• BURNIE J, CARTER T, RIGG G et al.: Identification of ABC transporters in vancomycin-resistant Enterococcus faecium as potential targets for antibody therapy. FEMS Immunol. Med. Microbiol. (2002) 33(3):179-189.
   PubMed Web of Science ®Google Scholar
• MEEHL M, HERBERT S, GOETZ F et al.: Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. (2007) 51(8):2679-2689.
   PubMed Web of Science ®Google Scholar
• CHOUDHRY V, ZHANG MY, DIMITROVA D et al.: Antibody-based inhibitors of HIV infection. Expert Opin. Biol. Ther. (2006) 6(5):523-531.
   PubMed Web of Science ®Google Scholar
• TRKOLA A, KUSTER H, RUSERT P et al.: Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. (2005) 11(6):615-622.
   PubMed Web of Science ®Google Scholar
• MANRIQUE A, RUSERT P, JOOS B et al.: In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5 and 4E10. J. Virol. (2007) 81(16):8793-8808.
   PubMed Web of Science ®Google Scholar
• HELLE F, GOFFARD A, MOREL V et al.: The neutralizing activity of anti-HCV antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. (2007) 81(15):8101-8111.
   PubMed Web of Science ®Google Scholar
• NUIJTEN MJ, WITTENBERG W, LEBMEIER M: Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics (2007) 25(1):55-71.
   PubMed Web of Science ®Google Scholar
• WU H, PFARR DS, JOHNSON S et al.: Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. (2007) 368(3):652-665.
   PubMed Web of Science ®Google Scholar
• JESTER PM, TILDEN SJ, LI Y et al.: Regulatory challenges: lessons from recent West Nile virus trials in the United States. Contemp. Clin. Trials (2006) 27(3):254-259.
   PubMed Web of Science ®Google Scholar
• NORRIS D, MORALES J, GODOFSKY E et al.: TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in Phase II study at 48 weeks. Int. Conf. AIDS (2006) 16:(Abstract No. ThLB0218).
   Google Scholar
• MURGA JD, FRANTI M, PEVEAR DC et al.: Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. (2006) 50(10):3289-3296.
   PubMed Web of Science ®Google Scholar
• LALEZARI J et al.: A Phase I, dose-escalation, placebo-controlled study of a fully human monoclonal antibody (CCR5mAb004) against CCR5 in patients with CCR5-tropic HIV-1 infection. 46th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco (2006) (Abstract H-1668).
   Google Scholar
• SHIBATA J, YOSHIMURA K, HONDA A et al.: Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. J. Virol. (2007) 81(8):3757-3768.
   PubMed Web of Science ®Google Scholar
• SCHIANO TD, CHARLTON M, YOUNOSSI Z et al.: Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a Phase II randomized study. Liver Transplant. (2006) 12(9):1381-1389.
   PubMed Web of Science ®Google Scholar
• DAGAN S, EREN R: Therapeutic antibodies against viral hepatitis. Curr. Opin. Mol. Ther. (2003) 5(2):148-155.
   PubMed Web of Science ®Google Scholar
• SOARES M, SYED S, BARBERO G et al.: Antibody mediated targeting of “inside-out” anionic phospholipids in viral disease. J. Immunol. (2007) 178:47.21 (Meeting Abstract).
   Google Scholar
• GALUN E, EREN R, SAFADI R et al.: Clinical evaluation (Phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatology (2002) 35(3):673-679.
   PubMed Web of Science ®Google Scholar
• CARDENAS S, AUAIS A, PIEDIMONTE G: Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev. Anti Infect. Ther. (2005) 3(5):719-726.
   PubMedGoogle Scholar
• CARBONELL X, LOSONSKY G, HULTQUIST M et al.: Phase III trial of motavizumab (MEDI-524), an enhanced potency respiratory syncytial virus (RSV) specific monoclonal antibody (Mab) for the prevention of serious rsv disease in high risk infants. Abstract [8220.9]. Ped. Acad. Soc. Ann. Meeting, Toronto, Canada (2007).
   Google Scholar
• GOUDSMIT J, MARISSEN WE, WELDON WC et al.: Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J. Infect. Dis. (2006) 193(6):796-801.
   PubMed Web of Science ®Google Scholar
• MOHAMED N, CLAGETT M, LI J et al.: A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. (2005a) 73(2):795-802.
   PubMed Web of Science ®Google Scholar
• SUBRAMANIAN GM, CRONIN PW, POLEY G et al.: A Phase I study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin. Infect. Dis. (2005) 41(1):12-20.
   PubMed Web of Science ®Google Scholar
• VITALE L, BLANSET D, LOWY I et al.: Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect. Immun. (2006) 74(10):5840-5847.
   PubMed Web of Science ®Google Scholar
• RIGG GP, MATTHEWS RC, DONOHOE MS et al.: Aurograb shows broad spectrum synergy with vancomycin against MRSA and VISA (vancomycin-intermediate) strains of Staphylococcus aureus. 42nd Interscience Conference Antimicrobial Agents Chemotherapy (ICAAC), (27 – 30 September 2002) 42:(Abstract No. E-1645).
   Google Scholar
• THACKRAY H, LASSITER H, WALSH W et al.: Phase II randomized, double blind, placebo-controlled, safety, pharmacokinetics (PK), and clinical activity study in very low birth weight (VLBW) neonates of pagibaximab, a monoclonal antibody for the prevention of Staphylococcal infection. Pediatr. Res. (2006) 59(4).
   Google Scholar
• WEEMS JJ Jr, STEINBERG JP, FILLER S et al.: Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. (2006) 50(8):2751-2755.
   PubMed Web of Science ®Google Scholar
• LANG AB, HORN MP, IMBODEN MA et al.: Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients. Vaccine (2004) 6(22) (Suppl. 1):S44-S48.
   Google Scholar
• FRANK DW, VALLIS A, WIENER-KRONISH JP et al.: Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J. Infect. Dis. (2002) 86(1):64-73.
   Google Scholar
• BABCOCK GJ, BROERING TJ, HERNANDEZ HJ et al.: Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. (2006) 74(11):6339-6347.
   PubMed Web of Science ®Google Scholar
• PACHL J, SVOBODA P, JACOBS F et al.: A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. (2006) 42(10):1404-1413.
   PubMed Web of Science ®Google Scholar
• DAVIS GL, NELSON DR, TERRAULT N et al.: A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (civacir) in liver transplant recipients. Liver Transplant. (2005) 11(8):941-949.
   PubMed Web of Science ®Google Scholar
• BENJAMIN DK, SCHELONKA R, WHITE R et al.: A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J. Perinatol. (2006) 26(5):290-295.
   PubMed Web of Science ®Google Scholar
• VERNACHIO JH, BAYER AS, AMES B et al.: Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob. Agents Chemother. (2006) 50(2):511-518.
   PubMed Web of Science ®Google Scholar
• BAKER M: Anti-infective antibodies: finding the path forward. Nat. Biotechnol. (2006) 24(12):1491-1493.
   PubMed Web of Science ®Google Scholar
• REICHERT JM: Trends in the development and approval of monoclonal antibodies for viral infections. Biodrugs (2007) 21(1):1-7.
   PubMed Web of Science ®Google Scholar
• REICHERT JM, DEWITZ MC: Anti-infective monoclonal antibodies: perils and promise of development. Nat. Rev. Drug Discov. (2006) 5(3):191-195.
   PubMed Web of Science ®Google Scholar
• HOLLIGER P, HUDSON PJ: Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. (2005) 23(9):1126-1136.
   PubMed Web of Science ®Google Scholar

Website

• http://www.emea.europa.eu/pdfs/human/opinion/12972307en.pdf
   Google Scholar